Lawrence Steinman, MD

Professor of Neurology and Neurological Sciences, Pediatrics, and Genetics; and head, Steinman Lab, Stanford Medicine

Articles

Epstein-Barr Virus and MS: Exploring Implications From Bench to Bedside

February 21, 2022

Alberto Ascherio, MD, DrPH, and Lawrence Steinman, MD, join NeurologyLive in a conversation about the clinical and research implications of a causative relationship between Epstein-Barr virus and multiple sclerosis.

Advances in MS Treatment, ECTRIMS 2021 Takeaways: Lawrence Steinman, MD

October 20, 2021

Discussing this year’s virtual ECTRIMS conference, the Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University provided his opinion on recent developments in the MS field. [WATCH TIME: 3 minutes]

Impact of Ublituximab for Patients With Relapsing MS: Lawrence Steinman, MD

October 19, 2021

The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University discussed the treatment’s potential in the multiple sclerosis space, where there are other competing drugs with similar safety profiles. [WATCH TIME: 4 minutes]

Expanded Data from ULTIMATE 1 and 2 Trials of Ublituximab: Lawrence Steinman, MD

October 15, 2021

The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University spoke on the safety and efficacy of ublituximab in treating patients with relapsing forms of multiple sclerosis. [WATCH TIME: 4 minutes]

Future Direction of MS Treatment

June 10, 2021

Key opinion leaders in neurology, Lawrence Steinman, MD and Enrique Alvarez, MD, PhD, reflect on future developments in the management of multiple sclerosis and share key advice for community physicians.

Ublituximab for MS: The ULTIMATE I and II Trials

June 03, 2021

Experts in the management of multiple sclerosis provide key insights into the use of ublituximab in multiple sclerosis and review results of the ULTIMATE I and II trials from the AAN 2021 Annual Meeting.  

Monitoring Response and Sequencing Therapies in RRMS

June 03, 2021

Enrique Alvarez, MD, PhD reviews factors to consider when monitoring response to treatment, and Lawrence Steinman, MD comments on patient- and disease-related factors that may impact therapeutic sequencing.

Selecting a High-Efficacy Therapy for RRMS 

May 27, 2021

Two experts in multiple sclerosis share insights on the shared decision-making process when selecting a high efficacy therapy and emphasize the importance of disease characteristics and patient preference.

Advantages of High-Efficacy Therapy in RRMS

May 27, 2021

Key opinion leaders in neurology, Lawrence Steinman, MD and Enrique Alvarez, MD, PhD examine some advantages associated with beginning patients on higher-efficacy therapies for relapsing/remitting multiple sclerosis.